Research Antibodies Market Analysis

Product (Primary Antibodies, Secondary Antibodies)

Primary antibodies segment is anticipated to dominate over 77.3% research antibodies market share by 2037. The key segment driver is the rising demand for tools to study and understand biological processes. These antibodies are used for research applications for immunohistochemistry, flow cytometry, and western blotting among others. The segment has also been boosted by the expansion of research activities in biotechnology and genomics. For instance, in 2021, the University of Cambridge developed single-domain antibodies (sdAbs) that can be used for treating acute coronary syndrome.

The secondary antibodies segment is expected to have considerable growth during the forecast period due to their role in improving detection sensitivity. The development of advanced detection techniques such as flow cytometry and fluorescence microscopy has enabled the growth of this segment. Key players in this segment are actively trying to improve measurement accuracy and reduce background noise. For example, Invitrogen Alexa Fluor Plus secondary antibodies were developed by ThermoFisher for a high signal-to-noise ratio.

Source (Rabbit, Mouse, Goat)

The rabbit monoclonal antibody segment in research antibodies market is expected to hold a significant revenue share during the forecast period owing to its versatility. Rabbit monoclonal antibodies are used in various research techniques such as flow cytometry, immunohistochemistry, and western blotting. The adaptability increases their applications, thereby boosting research antibodies market growth. The key players in this segment are expanding their portfolio and investing in research & development activities to expand their market shares.

In February 2023, Roche launched the IDH1 R132H rabbit monoclonal primary antibody to identify mutation strains in patients diagnosed with brain tumors. In November 2022, Bruker Cellular Analysis launched Opto Memory B Discovery Rabbit Worfklow which assists in the discovery of rabbit antibodies suitable for research and diagnostics.

Type (Monoclonal Antibodies, Polyclonal Antibodies) 

The monoclonal antibodies segment in research antibodies market is expected to register rapid revenue CAGR between 2025 and 2037 due to the increasing prevalence of chronic diseases, advancements in biotechnology, and the growing need for personalized medicine. Polyclonal antibodies help in testing for diseases such as herpes and HIV. The increased investments in research and development have enabled the primary market players of this segment to access new research breakthroughs. For instance, in May 2024, AstraZeneca’s Sipavibart trial demonstrated a decreasing level of COVID-19 symptoms in an immunocompromised population.

The polyclonal antibodies segment is also poised for significant growth during the forecast period owing to its cost-effectiveness. Advancements in antigen preparation have enabled the development of polyclonal antibodies with improved specificity. For instance, in 2021, ACTG announced the graduation of a novel polyclonal antibody therapy, SAB 185, for a phase 3 study.

Our in-depth analysis of the global research antibodies market includes the following segments: